Physician profile
Brian C Mcmorrow
NPI 1851391890
$686.43
in general payments reported to CMS, 2019-2025
10 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $116 · 2023: $161 · 2024: $27.44 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.90 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $207.25 | 2021-2025 | |
| Janssen Biotech, INC. | $157.46 | 2021-2025 | Tremfya |
| Braintree Laboratories, INC. | $137.21 | 2021 | |
| Genzyme Corporation | $52.06 | 2023-2025 | |
| Celgene Corporation | $30.52 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.17 | 2022-2023 | Trulance |
| Daiichi Sankyo INC. | $25.08 | 2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $18.10 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $17.78 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $10.80 | 2023 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcmorrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.